newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV

ZTALMY is approved by the U.S. Food and Drug Administration and the European Commission for appropriate patients with CDKL5 deficiency disorder The program enables physicians to request ZTALMY for eligible patients in